First-line fulvestrant plus anastrozole for hormone-receptor-positive metastatic breast cancer in postmenopausal women: a cost-effectiveness analysis

被引：0
|
作者：
Weiting Liao
Jiaxing Huang
Qiuji Wu
Feng Wen
Nan Zhang
Kexun Zhou
Liangliang Bai
Qiu Li
机构：
[1] Sichuan University,Department of Medical Oncology, Cancer Center, West China Hospital
[2] Sichuan University,West China Biomedical Big Data Center
来源：
Breast Cancer | 2020年 / 27卷
关键词：
Cost-effectiveness analysis; Breast cancer; Hormone-receptor-positive; Fulvestrant; Anastrozole; Dual endocrine therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：399 / 404
页数：5
相关论文
共 50 条
  • [1] First-line fulvestrant plus anastrozole for hormone-receptor-positive metastatic breast cancer in postmenopausal women: a cost-effectiveness analysis
    Liao, Weiting
    Huang, Jiaxing
    Wu, Qiuji
    Wen, Feng
    Zhang, Nan
    Zhou, Kexun
    Bai, Liangliang
    Li, Qiu
    BREAST CANCER, 2020, 27 (03) : 399 - 404
  • [2] Cost-effectiveness analysis of fulvestrant versus anastrozole as first-line treatment for hormone receptor-positive advanced breast cancer
    Ding, H.
    Fang, L.
    Xin, W.
    Tong, Y.
    Zhou, Q.
    Huang, P.
    EUROPEAN JOURNAL OF CANCER CARE, 2017, 26 (06)
  • [3] Cost-effectiveness of anastrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer
    Simons, WR
    Jones, D
    Buzdar, A
    CLINICAL THERAPEUTICS, 2003, 25 (11) : 2972 - 2987
  • [4] A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer
    Robert W. Carlson
    Anne O’Neill
    Tatiana Vidaurre
    Henry L. Gomez
    Sunil S. Badve
    George W. Sledge
    Breast Cancer Research and Treatment, 2012, 133 : 1049 - 1056
  • [5] A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer
    Carlson, Robert W.
    O'Neill, Anne
    Vidaurre, Tatiana
    Gomez, Henry L.
    Badve, Sunil S.
    Sledge, George W.
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 133 (03) : 1049 - 1056
  • [6] Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer in Korea
    Beom, Seung Hoon
    Oh, Jisu
    Kim, Tae-Yong
    Lee, Kyung-Hun
    Yang, Yaewon
    Suh, Koung Jin
    Moon, Hyeong-Gon
    Han, Sae-Won
    Oh, Do-Youn
    Han, Wonshik
    Kim, Tae-You
    Noh, Dong-Young
    Im, Seock-Ah
    CANCER RESEARCH AND TREATMENT, 2017, 49 (02): : 454 - 463
  • [7] A meta-analysis of anastrozole in combination with fulvestrant in the first line treatment of hormone receptor positive advanced breast cancer
    Pui San Tan
    Benjamin Haaland
    Alberto J. Montero
    Gilberto Lopes
    Breast Cancer Research and Treatment, 2013, 138 : 961 - 965
  • [8] A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer
    Hiroji Iwata
    Norikazu Masuda
    Shinji Ohno
    Yoshiaki Rai
    Yasuyuki Sato
    Shozo Ohsumi
    Satoshi Hashigaki
    Yoshinori Nishizawa
    Masahiro Hiraoka
    Tadaoki Morimoto
    Hironobu Sasano
    Toshiaki Saeki
    Shinzaburo Noguchi
    Breast Cancer Research and Treatment, 2013, 139 : 441 - 451
  • [9] A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer
    Iwata, Hiroji
    Masuda, Norikazu
    Ohno, Shinji
    Rai, Yoshiaki
    Sato, Yasuyuki
    Ohsumi, Shozo
    Hashigaki, Satoshi
    Nishizawa, Yoshinori
    Hiraoka, Masahiro
    Morimoto, Tadaoki
    Sasano, Hironobu
    Saeki, Toshiaki
    Noguchi, Shinzaburo
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 139 (02) : 441 - 451
  • [10] Cost-effectiveness analysis of ribociclib plus fulvestrant for hormone receptor-positive/human EGF receptor 2-negative breast cancer
    Jiang, Wei
    He, Zhichao
    Zhang, Tiantian
    Guo, Chongchong
    Zhao, Jianli
    Zhu, Jianhong
    Wu, Junyan
    Yu, Xiaoxia
    Chen, Chuxiong
    Li, Jianfang
    Jiang, Jie
    IMMUNOTHERAPY, 2021, 13 (08) : 661 - 668
12345